Выбор редакции

Boston Scientific (BSX) and the University of Rochester Medical Center announce positive results from their clinical trial - which studied whether alternate programming could reduce the occurrence of inappropriate therapy in primary prevention patients - showed that improved programming of [[BSX]]'s implantable defibrillators can in fact reduce such occurrences as well as lower overall risk of death.

Boston Scientific (BSX) and the University of Rochester Medical Center announce positive results from their clinical trial - which studied whether alternate programming could reduce the occurrence of inappropriate therapy in primary prevention patients - showed that improved programming of BSX's implantable defibrillators can in fact reduce such occurrences as well as lower overall risk of death. Post your comment!

НОВОСТИ ПО ТЕМЕ